Contamination by human and veterinary pharmaceutical derivatives refers to the undesirable presence of drug residues in the environment, including water, soil, and living organisms. This contamination can occur at various stages, including production, consumption, and disposal of medications. Main sources include releases from pharmaceutical facilities, wastewater discharges containing drug residues, and uncontrolled use of veterinary drugs in agriculture.
Pharmaceutical contamination raises environmental and health concerns, impacting ecosystems and posing risks of antibiotic-resistant bacteria emergence. Conventional wastewater treatment methods may not efficiently remove these compounds, contributing to their persistence. Efforts are underway to develop advanced treatment technologies and sustainable pharmaceutical waste management practices. Regulations aim to limit releases and promote environmental monitoring to assess the extent of contamination by pharmaceutical derivatives.

Pharmaceuticals

Contamination by human and veterinary pharmaceutical derivatives refers to the undesirable presence of drug residues in the environment, including water, soil, and living organisms. This contamination can occur at various stages, including production, consumption, and disposal of medications. Main sources include releases from pharmaceutical facilities, wastewater discharges containing drug residues, and uncontrolled use of veterinary drugs in agriculture. Pharmaceutical contamination raises environmental and health concerns, impacting ecosystems and posing risks of antibiotic-resistant bacteria emergence. Conventional wastewater treatment methods may not efficiently remove these compounds, contributing to their persistence. Efforts are underway to develop advanced treatment technologies and sustainable pharmaceutical waste management practices. Regulations aim to limit releases and promote environmental monitoring to assess the extent of contamination by pharmaceutical derivatives.

INTERFERON GAMMA-1B FOR SYSTEM SUITABILITY CRS (0.6 MG)

INTERFERON GAMMA-1B FOR SYSTEM SUITABILITY CRS (0.6 MG)

98059-61-1

DISCOVER
PROGESTERONE FOR SYSTEM SUITABILITY CRS (5 MG)

PROGESTERONE FOR SYSTEM SUITABILITY CRS (5 MG)

NA

DISCOVER
PROGESTERONE FOR PEAK IDENTIFICATION CRS (5 MG)

PROGESTERONE FOR PEAK IDENTIFICATION CRS (5 MG)

NA

DISCOVER
PROGESTERONE FOR IMPURITY H IDENTIFICATION CRS (25 MG)

PROGESTERONE FOR IMPURITY H IDENTIFICATION CRS (25 MG)

NA

DISCOVER
METHOTREXATE FOR SYSTEM SUITABILITY CRS (100 MG)

METHOTREXATE FOR SYSTEM SUITABILITY CRS (100 MG)

NA

DISCOVER
SODIUM AMINOSALICYLATE DIHYDRATE CRS (20 MG)

SODIUM AMINOSALICYLATE DIHYDRATE CRS (20 MG)

6018-19-5

DISCOVER
MELDONIUM DIHYDRATE CRS (10 MG)

MELDONIUM DIHYDRATE CRS (10 MG)

86426-17-7

DISCOVER
MELDONIUM IMPURITY A CRS (25 MG)

MELDONIUM IMPURITY A CRS (25 MG)

2840-24-6

DISCOVER
MELDONIUM IMPURITY B CRS (25 MG)

MELDONIUM IMPURITY B CRS (25 MG)

34810-18-9

DISCOVER
MELDONIUM IMPURITY C CRS (25 MG)

MELDONIUM IMPURITY C CRS (25 MG)

106966-25-0

DISCOVER
MELDONIUM IMPURITY D CRS (25 MG)

MELDONIUM IMPURITY D CRS (25 MG)

76144-84-8

DISCOVER
MELDONIUM IMPURITY E CRS (25 MG)

MELDONIUM IMPURITY E CRS (25 MG)

NA

DISCOVER